InGeneron

📢 InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System.

This study completes a decade of scientific validation of our therapeutic approach through peer-reviewed data:

✅ Consistent cell characterization
✅ In Vivo Regeneration
✅ Human Biopsy Evidence
✅ Clinical Trial Data

🔬 Read the full announcement:
👉 https://ingeneron.com/?p=2929

InGeneron reports positive long-term results for its cell therapy in partial-thickness rotator cuff tears. The randomized controlled trial, published in Nature's Scientific Reports, met primary endpoints, and finds statistically significant durable patient benefit 3.4 years post-treatment.

To read the full press release, please visit

InGeneron Reports Positive Long-Term Results for Cell Therapy Randomized controlled trial meets primary endpoint and finds statistically significant durable patient benefit 3.4 years post-treatment.

InGeneron is committed to advancing the field of regenerative medicine through our innovative cellular therapy products. Learn more about our technology and approach at https://ingeneron.com/

InGeneron is led by an international team of bold innovators creating the next generation of life-changing therapeutics. One of the most influential people behind this new age of regenerative medicine is our Executive Chairman, Dr. Eckhard Alt.

Dr. Alt is a frequent reviewer and serves on the editorial boards of respected journals. From 2001 to 2007, he was president of the Cardiac Electrophysiology Society. He has organized major national and international congresses; authored more than 500 publications in peer-reviewed journals, books, or book chapters; and has acquired more than 600 worldwide patents, primarily in the fields of stem cells, electrophysiology, and interventional cardiology.

Learn more about his story and the rest of our team by visiting our website: https://ingeneron.com/leadership/

Happy Juneteenth!